871025-07-9 Usage
Uses
Used in Pharmaceutical Industry:
4-Chloro-6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyrimidine is utilized as a building block in the synthesis of novel drugs, capitalizing on its capacity to interact with biological targets. Its unique structure allows it to be a valuable component in the development of new therapeutic agents.
Used in Medicinal Chemistry Research:
4-chloro-6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidine serves as a research tool in medicinal chemistry, aiding scientists in understanding the interactions between small molecules and biological systems. Its distinctive properties make it instrumental in drug discovery processes, where it can be employed to study and develop new therapeutic approaches.
Used in Drug Discovery:
4-Chloro-6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyrimidine is applied in drug discovery to explore its potential therapeutic properties. Its capacity to engage with biological targets makes it a promising candidate for further research and development into new pharmaceuticals with specific applications in treating various diseases or conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 871025-07-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,1,0,2 and 5 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 871025-07:
(8*8)+(7*7)+(6*1)+(5*0)+(4*2)+(3*5)+(2*0)+(1*7)=149
149 % 10 = 9
So 871025-07-9 is a valid CAS Registry Number.
871025-07-9Relevant academic research and scientific papers
FUSED HETEROCYCLIC COMPOUND
-
Page/Page column 142, (2008/06/13)
The present invention relates to a compound represented by the formula: wherein W is C(R 1 ) or N, each A is an optionally substituted aryl group or a heteroaryl group, X 1 is -NR 3 -Y 1 -, -O-, -S-, -SO-, -SO 2 or -CHR 3 - wherein R 3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R 3 is optionally bonded to A to form an optionally substituted ring structure, R 1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R 2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R 1 and R 2 , or R 2 and R 3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.
